Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Beats on EPS, Stock Up 3.42%

Catalyst Pharmaceuticals reported a strong EPS performance, which exceeded expectations, leading to a positive stock reaction of 3.42%. The lack of revenue data means investors are focused primarily on the EPS beat. Management's cautious optimism suggests they are confident in their current trajectory but did not provide specific guidance for the future.